OliX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company and leading developer of RNAi therapeutics, announced that the Alfred Human Research Ethics Committee (HREC) has approved the company to conduct a phase 1 clinical trial of...
AstraZeneca announced a $1.2 billion acquisition of Gracell Biotechnologies as the Anglo-Swedish pharma firm expands its cell treatment ambitions and expands its footprint in China, the world's second-largest pharmaceuticals market. The cash...
Bristol Myers Squibb and neuroscience-focused Karuna Therapeutics, Inc announced a definitive merger agreement in which Bristol Myers Squibb will acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7...
A related party has reached a definitive agreement with Cosmos Health Inc., a Chicago-based diversified, vertically integrated global healthcare group that engages in innovative research and development, owns proprietary pharmaceutical and...
Wainua (eplontersen) from AstraZeneca and Ionis has been licensed in the United States for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, also known as hATTR-PN or ATTRv-PN. Wainua is the only licensed...
The domestic pharmaceutical industry anticipates another year of continuous growth in 2024, despite a number of hurdles, such as maintaining quality standards while transitioning from volume to value leadership. To satisfy the increasing...
Ono Pharmaceutical Co., Ltd announced a discovery collaboration agreement with EVQLV, INC to create novel antibodies against diverse targets chosen by Ono for the development of novel antibody medicines. Under the agreement, EVQLV will generate...
Aptar Digital Health, a global leader in software as a medical device (SaMD), digital Patient Support Programmes (PSPs), and disease management solutions, has announced a new collaboration with Legit.Health, a cutting-edge artificial intelligence...
As per AstraZeneca Pharma India Limited, Trastuzumab Deruxtecan, also known as Enhertu, will be accessible in January 2024 for the treatment of HER2-positive breast cancer. The company received clearance from the Central Drugs Standard Control...
The Research Council of Norway has awarded NOK 16 million to Hemispherian AS, an Oslo-based Norwegian preclinical pharmaceutical business concentrating on small molecule cancer therapies. Hemispherian's GLIX patented chemicals target a unique...
, CDSCO.jpg)
.jpg)